Kling Bio and Sanofi Partner to Fast-Track Neutralizing Antibody Discovery

Biotech company Kling Bio has announced a new collaboration and license option agreement with global pharmaceutical giant Sanofi aimed at accelerating the discovery of neutralizing antibodies targeting viral pathogens.

The partnership will leverage Kling Bio’s proprietary B cell immortalization and screening platform, Kling-Select, a clinically validated technology designed to identify potent antibodies and conserved viral epitopes from patient-derived B cells. The platform has already demonstrated success in discovering promising candidates against RSV, COVID-19, and influenza.

By applying Kling-Select’s unique function-first screening capabilities, the collaboration seeks to uncover rare and highly effective monoclonal antibodies with the potential to neutralize a clinically relevant human viral pathogen. The joint effort could pave the way for next-generation antiviral therapies and inform future vaccine designs.

“This collaboration with Sanofi highlights the broad potential of our Kling-Select platform to address global health challenges by enabling the discovery of first-in-class, human-derived antibodies,” said Dr. Michael Koslowski, CEO of Kling Bio. “We are excited to combine our expertise with Sanofi’s leadership in vaccine development to advance next-generation therapeutics and vaccines.”

The agreement reinforces the growing interest in function-first immune profiling and human-derived antibodies as tools for faster and more precise medical interventions in infectious disease.